You are here
Aripiprazole Gains Priority Review for the Treatment of Pediatric Patients with Schizophrenia
About Abilify (aripiprazole)
The first and only available dopamine partial agonist, Abilify is indicated for the short- and long-term treatment of schizophrenia including maintaining stability in adults who had been symptomatically stable on other antipsychotic medications for periods of three months or longer and observed for relapse during a period of up to 26 weeks. Abilify is also indicated for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder, and for maintaining efficacy in adults with Bipolar I Disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least six (6) weeks. Physicians who elect to use Abilify for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual. Abilify Injection is indicated for the treatment of agitation associated with schizophrenia or bipolar disorder, manic or mixed.
Source: Otsuka Pharmaceutical and Bristol-Myers Squibb